Clinical trials
Gastrointestinal Stromal Tumors clinical trials
Below are recruiting gastrointestinal stromal tumors clinical trials, each written for real people, not researchers. We’re tracking 51 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07559864RecruitingPhase 2
Regorafenib plus Envafolimab for treatment-resistant gastrointestinal stromal tumors
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07550582Enrolling by invitationPhase 2
Surgery for small tumors at the food pipe opening
This trial tests a new surgical approach combining laparoscopic (minimally invasive) surgery with endoscopy (a camera procedure) to remove small tumors located where the esophagus meets the stomach. The goal is to safely remove these tumors while preserving normal function.
Beijing, Beijing MunicipalityAges 18–80 - NCT01048281Recruiting
Study of stomach and esophagus cancer samples
This study looks at stomach (gastric) and esophagus cancer, using clinical information and tissue samples. It may help researchers better understand these cancers and improve future care.
Stanford, CaliforniaAges 18 years+ - NCT03716089Recruiting
Laparoscopic surgery for stomach GIST by tumor site
This trial studies whether doing laparoscopic surgery for stomach GISTs (gastrointestinal stromal tumors) works and is safe when the tumor is in a “favorable” versus “unfavorable” location. You might be eligible if your tumor is confirmed as GIST and doctors expect to remove it completely using keyhole surgery.
Fuzhou, FujianAges 18–75 - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT07618377RecruitingPhase 1
New Drug for Gastrointestinal Tumors After Multiple Treatments
This study tests a new drug called DCC-2618 for patients with GIST (a rare stomach/intestinal cancer) who have already tried at least three other treatments. The goal is to see if this drug can slow or shrink tumors in patients whose cancer has stopped responding to standard medications.
Kashiwa, ChibaAges 18 years+ - NCT03602092Recruiting
GIST patient registry to improve real-world care
This observational study keeps a registry of people diagnosed with gastrointestinal stromal tumor (GIST) to collect real-life information over time. It may help doctors better understand outcomes and care patterns for future patients.
TaipeiAges 20 years+ - NCT04181970Recruiting
Study of sarcoma care quality across Europe and Latin America
This observational study looks at information from people with sarcoma to understand how care is delivered across different centers. It does not test a new treatment, but may help improve future care and planning.
Buenos AiresAges 18–120 - NCT05366816RecruitingPhase 2
Blood test–guided sunitinib or regorafenib for GIST
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
Miami, FloridaAges 18 years+ - NCT05408897Recruiting
Blood test to predict risk after surgery for high-risk GIST
This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.
Beijing, Beijing MunicipalityAges Any age - NCT05493215RecruitingPhase 2
Imatinib drug-monitoring for GIST with specific gene changes
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
Lexington, KentuckyAges 18 years+ - NCT05661643RecruitingPhase 2
Temozolomide for GIST tumors with SDH deficiency
This trial tests how well temozolomide works and how safe it is for people with GIST (a type of stomach/intestine tumor) that is SDH-deficient and has no KIT or PDGFRα mutations. It may help by targeting tumor DNA repair weakness seen in this SDH-deficient subtype.
Seoul, SeoulAges 20 years+ - NCT05751733Recruiting
Apatinib versus standard drug for advanced GIST after imatinib
This trial studies whether apatinib works better than the usual second-line targeted tablet for advanced gastrointestinal stromal tumor (GIST) after imatinib (or avatinib) no longer works. It may help people whose cancer has grown despite treatment or who couldn’t tolerate it.
Changsha, HunanAges 18 years+ - NCT05867901Recruiting
Test stopping imatinib early using blood DNA tests
This trial studies whether some people with high-risk GIST can safely take a “drug holiday” (pause imatinib) after surgery. They use a blood test looking for leftover cancer DNA to help decide who may benefit from stopping treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT06326346RecruitingPhase 2
Oral paclitaxel for advanced GIST after other treatments fail
This trial tests an oral form of paclitaxel (a chemotherapy drug) for people with advanced gastrointestinal stromal tumor (GIST) that has stopped responding to or caused side effects with imatinib, sunitinib, and regorafenib. It aims to see if this treatment can help when other options have run out.
Seoul, SongpaguAges 20 years+ - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT06507683Recruiting
Radiation plus ripretinib for advanced GIST
This trial tests whether adding radiation therapy to the drug ripretinib can help people with advanced gastrointestinal stromal tumors (GIST) that can't be removed by surgery and have stopped responding to other treatments. It aims to see if this combination is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06926374Recruiting
Robotic surgery for gastrointestinal and urologic conditions
This trial tests a new robotic surgery system for common operations on the colon, rectum, prostate, kidney, bladder, stomach, esophagus, gallbladder, and hiatal hernia. It may offer a less invasive option for patients who need surgery for these conditions.
Hong KongAges 18–80 - NCT01416714Recruiting
Tissue sample collection during cancer surgery or biopsy
This study is collecting tissue samples from people with certain cancers while they have surgery or a biopsy. It may help researchers learn more about these cancers and improve future diagnosis and treatment.
Chicago, IllinoisAges Any age - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Greenwood Village, ColoradoAges 19–110 - NCT07411118Recruiting
Comparing two ways to remove stomach GIST tumors with an endoscope
This trial compares two endoscopic techniques (EFTR and STER) for removing small to medium-sized GIST tumors from the stomach wall. It aims to see which method is safer and more effective.
ShanghaiAges 18–75 - NCT07434843RecruitingPhase 2
Pemigatinib for a rare type of GIST
This trial tests a drug called pemigatinib for people with a specific type of GIST (SDH-deficient GIST) that has spread or cannot be removed with surgery. The goal is to see if the drug can help stop the cancer from growing.
Boston, MassachusettsAges 18 years+ - NCT07673861Recruiting
Using ctDNA to find resistance and guide cancer treatment
This trial uses a simple blood test to look for changes in your cancer's DNA that might show why your current treatment stopped working. The results could help your doctor choose your next treatment more precisely.
LondonAges 18 years+ - NCT07581977Recruiting
A Clip Tool for Removing Small Stomach Growths
This trial tests a new two-tooth clip device designed to help doctors safely remove small gastrointestinal tumors (GISTs) from the stomach using endoscopy—a thin camera inserted through the mouth. The clip may make the removal procedure easier and safer.
BeijingAges 18–85
Hear when a new Gastrointestinal Stromal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastrointestinal stromal tumors?
- Yes. Clin2 currently lists 51 recruiting gastrointestinal stromal tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastrointestinal stromal tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastrointestinal stromal tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.